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Simple Summary: Hepatocellular carcinoma remains a leading cause of cancer-related death and
the most common primary hepatic malignancy in the Western hemisphere. Previous research found
that angiogenesis-related cytokines and elevated levels of interleukin 8 and vascular endothelial
growth factor (VEGF) shorten the expected time of survival. Moreover, factors of tumor angiogenesis-
and hypoxia-driven signaling pathways are already associated with worse outcome in disease-free
survival in several tumor entities. Our study investigates the prognosis of hepatocellular carcinoma
patients based on a selection of ten different single-nucleotide polymorphisms from angiogenesis,
carcinogenesis, and hypoxia pathways. Our study with 127 patients found supporting evidence that
polymorphisms in angiogenesis-associated pathways corelate with disease-free survival and clinical
outcome in patients with hepatocellular carcinoma.
Abstract: Tumor angiogenesis plays a pivotal role in hepatocellular carcinoma (HCC) biology.
Identifying molecular prognostic markers is critical to further improve treatment selection in these
patients. The present study analyzed a subset of 10 germline polymorphisms involved in tumor
angiogenesis pathways and their impact on prognosis in HCC patients undergoing partial hepatectomy
in a curative intent. Formalin-fixed paraffin-embedded (FFPE) tissues were obtained from 127 HCC
patients at a German primary care hospital. Genomic DNA was extracted, and genotyping was
carried out using polymerase chain reaction (PCR)–restriction fragment length polymorphism-based
protocols. Polymorphisms in interleukin-8 (IL-8) (rs4073; p = 0.047, log-rank test) and vascular
endothelial growth factor (VEGF C + 936T) (rs3025039; p = 0.045, log-rank test) were significantly
associated with disease-free survival (DFS). After adjusting for covariates in the multivariable model,
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IL-8 T-251A (rs4073) (adjusted p = 0.010) and a combination of “high-expression” variants of rs4073
and rs3025039 (adjusted p = 0.034) remained significantly associated with DFS. High-expression
variants of IL-8 T-251A may serve as an independent molecular marker of prognosis in patients
undergoing surgical resection for HCC. Assessment of the patients’ individual genetic risks may help
to identify patient subgroups at high risk for recurrence following curative-intent surgery.
Keywords: hepatocellular carcinoma; single-nucleotide polymorphism; IL8
1. Introduction
Hepatocellular carcinoma (HCC) is the most common primary hepatic malignancy, and its
mortality ranks fourth among solid tumors, behind carcinomas of the lung, colon, and the stomach [1,2].
As most HCCs develop in the background of chronic liver disease, liver transplantation is considered
the optimal curative therapy because it treats both the tumor and the underlying liver disease [3–6].
In the context of donor allograft shortage, surgical resection has emerged as a viable treatment strategy
even beyond early Barcelona Clinic Liver Cancer (BCLC) stages [3,7]. Despite continuous advances in
patient selection, surgical technique, and medical treatments [5,6], the rate of local tumor recurrence
exceeds 50% 4 years after partial hepatectomy [8,9]. Therefore, the implementation of prognostic
molecular markers as an adjunct to traditional staging systems may not only be helpful in identifying
patients prone to recurrence but can also aid patient-specific treatment selection.
In 1971, Judah Folkman introduced the hypothesis that angiogenesis, the formation of new
blood vessels from endothelial precursors, is a prerequisite for the growth and progression of solid
malignancies. Gaining access to the host vascular system and the generation of a tumor blood
supply are rate-limiting steps in tumor growth and progression [10]. Among proangiogenic factors,
vascular endothelial growth factor (VEGF), a sub-family of growth factors which is induced under
hypoxic conditions through hypoxia-inducible factor (HIF)-1α promotor binding, plays a pivotal role
in tumor angiogenesis [11,12]. The relevance of VEGF-dependent pathways for hepatocarcinogenesis
was recently emphasized by the data from a phase 3 clinical trial, establishing the combination therapy
of the VEGF inhibitor bevacizumab and the immune checkpoint inhibitor atezolizumab as the first-line
systemic treatment in advanced HCC [13].
Additionally, tumors can sustain angiogenesis in a VEGF-independent manner [14]. As such,
interleukin (IL)-8 (CXCL8) signaling preserves the angiogenic phenotype in HIF1-α-deficient colon
cancer cells, indicating a critical role of IL-8 in tumor-associated angiogenesis, independent of VEGF [15].
Furthermore, elevated serum levels of IL-8 and single-nucleotide polymorphisms (SNPs) of VEGF and
IL-8 are associated with shorter disease-free survival (DFS) and overall survival (OS) in HCC and other
gastrointestinal malignancies [16–20].
Based on these data, we here employed a pathway-focused approach to investigate whether
functional single-nucleotide polymorphisms of genes involved in angiogenesis, tumorigenesis,
and hypoxia (Table 1) are associated with differences in clinical outcome in HCC patients undergoing
partial hepatectomy in a curative intent.
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Table 1. Genes, their function, and the minor allele frequency.
No. Gene Allele SNP 1 Allele Function Minor Allele Freq. Description Ref.
1 IL-8 − 251 A > T rs4073 A-allele: higher IL-8 plasma levels 45% The dominant allele AT and AA is associated with a poor prognosis andmay increase CXCL 6, which stimulates endothelial production [21–25]
2 VEGF + 936 C > T rs3025039 T-allele: lower VEGF plasma levels 20%
De novo vascularization, endothelial proliferation
Increased risk of NASH
C-allele associated with higher VEGF production
[21,26–28]
3 EGFR-497 G > A rs2227983 A-allele: lower EGFR ligand binding,growth stimulation 29% Identified in gastrointestinal and colorectal tumors [29,30]
4 EGFA 61G A > G rs4444903 A-allele: lower EGF serum levels 45% Increased susceptibility to hepatitis C [30–32]
5 p53 C > G rs1042522 Tumor suppressor, induces cell cyclearrest 35%
Associates with LiFraumeni syndrome, is detected as inducer of different
types of cancer [33]
6 CXCR G > C rs2234671 C-allele: higher ligand binding 10% Interleukin-8 acts through CXCR receptor [34]
7 IL-1b C > T rs1143634 Increased tumor growth andproliferation 20% Stomach cell cancer, gall bladder cancer, breast cancer, and liver cell cancer [35]
8 HIF1 A588T C > T rs11549465 T-allele with cancer associated 8% Associated with tumor size and location in colorectal carcinoma,tumor tissue is over-stimulated with HIF1 [36,37]
9 IL-10 T > G rs1800872 Higher Il-10, moreimmunosuppressive effect 30–40%
Increases risk of liver cell cancer, negatively modulates NFKappaB and
TNF alpha production (inhibits gene expression) [38]
10 IL-6 G > C rs1800795 Proinflammatory cytokine, responseto cancer 20%
Increased risk of cervical and renal cancer
Stimulates endothelial production [39,40]
Abbreviations used: CI, confidence interval; VEGF, vascular endothelial growth factor; EGF, epidermal growth factor; EGFR, epidermal growth factor receptor; IL-1/6/8/10, interleukin-1/6/8/10;
CXC2, chemokine receptor; HIFa, hypoxia-inducing factor alpha; NASH, non-alcoholic fatty liver disease; NF-κB, nuclear factor kappa-light-chain-enhancer of activated B cells; TNF-alpha,
tumor-necrosis factor alpha; p53, protooncogene 53, 1 SNP, single nucleotide polymorphism Database NCBI.
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2. Results
2.1. Patients Characteristics
Between 2010 and 2017, 127 patients with localized hepatocellular carcinoma were included in this
study. Thirty-seven (37/127, 29.1%) patients were female and 90/127 (70.9%) were male; the median age
was 67 years (15–89). The median body mass index (BMI) was 27 kg/m2 (16.8–41). Sixty-four (64/127,
50.4%) patients had histologically confirmed cirrhosis, 76/127 (59.8%) had a single tumor, and 51/127
(39.3%) had more than one HCC lesion. Average diameter of tumor nodules on final pathology was 68
mm (6–228 mm). Median alpha-fetoprotein (AFP) at time of operation was 147.9 µL/L. Seventy-seven
(77/127, 60.6%) patients belonged to BCLC category 0/A and fifty (50/123, 39.4%) patients to category
B/C. Clinico-pathological characteristics are presented in Tables 2 and 3.
Table 2. Demographic and clinico-pathological characteristics and disease-free survival.






(95% CI) p Value
1
Sex
Female 37 (29.1%) 19 (51.4%) 38 (17.1–58.9) 0.763 (0.443–1.314) 0.329
Male 90 (70.9%) 43 (47.8%) 26 (16.1–35.3) 1 (reference)
Age (years) <65 48 (37.8%) 26 (44.2%) 26 (12.7–39.3) 1.222 (0.736–2.032) 0.438
>65 79 (62.2%) 36 (45.6%) 32 (17.0–47.0) 1 (reference)
BMI
<25 51 (40.2%) 22 (43.1%) 35 (15.4–54.6) 0.790 (0.469–1.330) 0.375
>25 76 (59.8%) 40 (52.6%) 26 (05.3–15.7) 1 (reference)
Diameter (mm) <50 49 (38.6%) 24 (49.0%) 39 (26.9–51.1) 0.695 (0.415–1.165) 0.168
>50 78 (61.4%) 38 (48.7%) 21 (12.5–29.5) 1 (reference)
T-category T1/2 95 (74.8%) 51 (53.7%) 39 (12.1–65.9) 0.407 (0.244–0.679) <0.0001
T3/4 32 (25.2%) 12 (37.5%) 12 (05.1–18.9) 1 (reference)
N-category 0 29 (22.8%) 13 (55.2%) 26 (05.4–47.0) 0.976 (0.543- 1.756) 0.936
N 98 (74.7%) 41 (44.8%) 30 (12.9–47.1) 1 (reference)
HCC tumor nodes
=1 51 (39.3%) 35 (68.6%) 12 (07.6–16.4) 0.543 (0.342–0.862) 0.0001
>1 76 (59.8%) 27 (35.5%) 67 (43.3–90.7) 1 (reference)
Steatosis
No 79 (61.9%) 39 (49.3%) 30 (18.2–41.8) 1.093 (0.652–1.833) 0.736
Yes 48 (38.1%) 23 (47.9%) 25 (0.00–61.7) 1 (reference)
Cirrhosis
No 63 (49.6%) 26 (41.3%) 58 (14.5–101.5) 0.519 (0.308–0.874) 0.012
Yes 64 (50.4%) 36 (48.8%) 24 (15.7–32.3) 1 (reference)
AFP (µL/L) <100 50 (39.4%) 27 (54.0%) 32 (22.4–41.6) 0.732 (0.455–1.180) 0.200
>100 77 (60.6%) 35 (55.5%) 24 (09.5–38.5) 1 (reference)
BCLC Stage 0/A 77 (57.5%) 33 (42.8%) 65 (33.6–96.4) 0.291 (0.171–0.496) <0.0001
B/C 50 (39.4%) 33 (66.0%) 11 (06.7–15.2) 1 (reference)
Values are given as median with 95% CI or numbers and (percentages). Results of the regression analysis are given
as relative risk with 95% confidence interval. Bold is used to highlight significant results. 1 Based on log-rank test.
BCLC—Barcelona Clinic Liver Cancer.
Table 3. Demographic and clinico-pathological characteristics and overall survival.






(95% CI) p Value
2
Sex
Female 37 (29.1%) 15 (40.5%) 78 (56.0–89.3) 0.410 (0.231–0.723) 0.002
Male 90 (70.9%) 59 (65.6%) 24 (16.0–32.0) 1 (reference)
Age (years) <65 48 (37.8%) 27 (46.2%) 38 (00.0–77.8) 0.840 (0.523–1.351) 0.473
>65 79 (62.2%) 47 (59.5%) 32 (18.7–45.3) 1 (reference)
BMI
<25 51 (40.2%) 28 (54.9%) 31 (12.3–49.7) 0.9 (0.562–1.441) 0.660
>25 76 (59.8%) 46 (60.5%) 35 (22.2–47.8) 1 (reference)
Diameter (mm) <50 49 (38.6%) 25 (51.0%) 58 (36.2–79.8) 0.601 (0.370–0.976) 0.035
>50 78 (61.4%) 49 (62.8%) 23 (15.6–30.4) 1 (reference)
T-category T1/2 95 (74.8%) 47 (51.6%) 47 (26.8–67.2) 0.261 (0.060–1.131) 0.002
T3/4 32 (25.2%) 24 (55.0%) 15 (06.4–23.6) 1 (reference)
N-category 0 29 (22.8%) 14 (48.3%) 65 (26.5–103.5) 0.591 (0.324–1.077) 0.082
N 98 (74.7%) 46 (59.0%) 32 (18.0–46.0) 1 (reference)
HCC tumor nodes
=1 51 (39.3%) 38 (50.0%) 42 (22.9–61.1) 0.543 (0.342–0.862) 0.010
>1 76 (59.8%) 35 (70.0%) 20 (12.0–28.0) 1 (reference)
Steatosis
No 79 (61.9%) 51 (65.4%) 30 (18.2–29.2) 1.590 (0.963–2.623) 0.070
Yes 48 (38.1%) 22 (45.8%) 58 (29.2–86.8) 1 (reference)
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Table 3. Cont.






(95% CI) p Value
2
Cirrhosis
No 63 (49.6%) 30 (47.6%) 55 (25.9–84.1) 0.515 (0.322–0.825) 0.005
Yes 64 (50.4%) 44 (68.7%) 24 (11.9–36.1) 1 (reference)
AFP (µL/L) <100 50 (39.4%) 27 (54.0%) 42 (18.8–65.2) 1.025 (0.618–1.699) 0.924
>100 77 (60.6%) 47 (61.0%) 29 (04.2–20.8) 1 (reference)
BCLC Stage 0/A 77 (57.5%) 33 (42.8%) 47 (27.7–66.2) 0.493 (0.309–0.789) 0.003
B/C 50 (39.4%) 33 (66.0%) 17 (09.1–24.9) 1 (reference)
Values are given as median with 95% CI, numbers and (percentages). Results of the regression analyses are given as
relative risk with 95% confidence interval. Bold is used to highlight significant results. 2 Based on log-rank test.
The median OS was 30.5 months (range 0–122 months), and the median DFS was 23 months
(range 0–117 months). During the observation period, 74 (58.2%) patients died and 62 (48.8%)
experienced tumor recurrence (Table 2). T-category 3 or 4 (p < 0.001), more than one tumor node
(p < 0.001), BCLC stage B/C (p < 0.001), and the presence of hepatic cirrhosis (p = 0.012) were significantly
associated with a shorter disease-free survival. T-category higher than 3 (p = 0.002), more than one
tumor nodule (p = 0.010), a tumor diameter over 50 mm (p value = 0.035), male sex (p = 0.002), and the
presence of hepatic cirrhosis (p = 0.005) were associated with shorter OS.
2.2. Analysis of IL-8 T-251A and Clinical Outcome
Genotyping of IL-8 T-251A was successful in 125 of 127 patients and was used for the subsequent
analysis. Of these, sixty-two (62/125, 49.6%) patients recurred, while 63/125 (50.4%) patients did not
show a recurrence within the observation period. An A/A genotype was identified in 14 (11.3%)
patients, who showed a median DFS of median 20 (0–40.1) months compared to 65 patients with the
T/T and 46 with the A/T allele with a median survival of 32 months (CI 18.34–5.8). IL-8 T-251A had
a minor allele frequency of 11.3% and was analyzed in a codominant model. The unfavorable A/A
allele was interpreted against A/T and T/T as favorable alleles (Table 4, Figure 1a). The p-value of the
log-rank test was 0.047 (Table 4, Figure 1a). IL-8 T-251A was included in the multivariable analysis.
IL-8 251 SNPs showed no significant association with OS.
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Figure 1. (a) Disease-free survival in the carriers of the interleukin-8 T-251A polymorphism, (b) the 
vascular endothelial growth factor C + 936T (VEGF) polymorphism and (c) the unfavorable alleles 
grouped together. Censored cases indicate the time of last follow-up for those patients who had 
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Figure 1. (a) Disease-free survival in the carriers of the interleukin-8 T-251A polymorphism, (b) the
vascular endothelial growth factor C + 936T (VEGF) polymorphism and (c) the unfavorable alleles
grouped together. Censored cases indicate the time of last follow-up for those patients who had neither
recurred nor died at the time of the analysis of data.
Table 4. Polymorphisms of genes analyzed and disease-free survival (DFS) as well as overall survival




(Months) (95% CI) RR (95% CI) p Value
Median OS (Months)
(95% CI) RR (95% CI) p Value
IL-8
0.047 0.366
AA 14 20 (8.7–40.1) 2.040 (1.000–4.179) 22 (8.7–35.3) 0.710 (0.337–1.479)




CT 1 41 20 (12.0–30.0) 1.668 (1.007–2.764) 27 (18.1–36.0) 1.038 (0.646–1.667)
TT 1 5
CC 81 41 (12.5–69.5) 1 (reference) 38 (27.0–50.0) 1 (reference)
IL-1
0.120 0.229
CC 54 51 (39.8–61.8) 0.583 (0.321–1.060) 38 (20.5–55.5) 0.657 (0.392–1.1)
TT 21 20 (12.1–27.8) 1.060 (0.545–2.063) 38 (0.0–90.0) 0.671 (0.335–1.342)
CT 43 25 (17.0–33.0) 1 (reference) 23 (8.0–38.0) 1 (reference)





(Months) (95% CI) RR (95% CI) p Value
Median OS (Months)
(95% CI) RR (95% CI) p Value
IL-6
0.301 0.415
GG 54 25 (11.8–38.2) 1.552 (0.873–2.759) 32 (16.9–47.1) 0.856 (0.522–1.404)
CC 23 32 (1.4–62.7) 1.458 (0.719–2.955) 65 (12.2–117.7) 0.632 (0.318–1.258)
GC 50 38 (2.7–73.3) 1 (reference) 30 (14.8–45.2) 1 (reference)
IL-10
0.580 0.456
TT 7 21 (6.4–35.6) 1.172 (0.343–4.009) 33 (17.3–47.8) 0.914 (0.271–3.079)
GG 74 30 (16.0–44.0) 1.356 (0.763–2.410) 30 (21.0–39.0) 1.359 (0.802–2.301)
GT 41 30 (13.0–47.0) 1 (reference) 41 (19.7–46.3) 1 (reference)
EGFA
0.145 0.073
AA 1 63 24 (0.9–47.1) 1.463 (0.877–2.441) 29 (15.8–42.2) 1.519 (0.959–2.406)
GG 1 10
AG 50 30 (13.2–46.8) 1 (reference) 38 (18.7–57.3) 1 (reference)
EGFR
0.393 0.523
GG 50 18 (7.8–28.2) 1.272 (0.721–2.243) 23 (14.0–32.0) 1.177 (0.703–1.972)
AA 27 38 (0.0–76.3) 0.807 (0.385–1.690) 38 (0–81.9) 0.819 (0.420–1.597)
AG 45 33 (23.1–42.9) 1 (reference) 47 (22.4–71.6) 1 (reference)
CXCR
0.693 0.847
GG 29 30 (13.4–46.6) 1.012 (0.527–1.941) 42 (4.8–79.2) 0.836 (0.455–1.538)
CC 11 21 (15.5–26.5) 1.414 (0.632–3.162) 30 (22.5–37.5) 0.960 (0.436–2.115)
GC 87 35 (17.4–52.6) 1 (reference) 31 (15.8–46.2) 1(reference)
p53
0.897 0.673
GG 43 38 (3.1–72.9) 0.653 (0.343–2.000) 38 (25.0–51.0) 0.944 (0.410–2.171)
CC 36 24 (7.8–40.2) 0.961 (0.528–1.800) 30 (12.0–48.1) 1.254 (0.687–2.3)
GC 16 25 (7.8–40.2) 1 (reference) 35 (15.4–55.0) 1 (reference)
HIF
0.229 0.779
CC 7 30 (16.7–43.4) 0.555 (0.135–2.279) 40 (0.0–90.4) 1.214 (0.439–3.355)
TT 18 56 (36.1–75.2) 0.518 (0.222–1.209) 23 (6.9–39.1) 1.223 (0.656–2.280)
CT 102 26 (18.7–41.3) 1 (reference) 35 (24.1–45.9) 1 (reference)
1 Polymorphisms were grouped together in a codominant model. Results of the regression analyses are given as
relative risk with 95% confidence interval. Bold is used to highlight significant results.
2.3. Analysis of VEGF C + 936T and Clinical Outcome
The genotyping of VEGF C + 936T was successful in all 127 patients. During the observation
period, 61/127 (48%) patients showed recurrence. Of these, 41 with allele C/C after 41 months (CI 5–77),
22 with C/T allele after 21 months (CI 8–4) and 5 with allele T/T after 6 months (CI 2–10), respectively.
The p-value of the log-rank test was 0.023 (Table 4, Figure 1b). Due to the small group of patients with
a T/T allele, we performed a dominant analysis (C/T and T/T grouped together) with a p-value of 0.045.
VEGF was included in the multivariable analysis. OS showed no significant association with the VEGF
SNP and was, therefore, not further analyzed.
2.4. Combined Analysis of VEGF C + 936T, IL-8 T-251A and Clinical Outcome
When VEGF C + 936T (adjusted p-value = 0.332) and IL-8-251 T > A (adjusted p-value = 0.010)
were stratified by cirrhosis, T-category, more than one tumor node, and polymorphisms in IL8 remained
significantly associated with DFS. VEGF C + 936T did not remain associated with DFS. Patients with
zero unfavorable alleles (IL-8-251 AT/TT and VEGF +936 CC allele) had lower risk of tumor recurrence
than patients with one unfavorable allele (RR 1.853 (1.045–3.284)) or two unfavorable genes (RR 4.910
(1.047–23.031), adjusted p-value 0.034) (Table 5, Figure 1c). The median disease-free survival was
20 months in the group with one unfavorable allele and was 7 months with two unfavorable alleles
compared to 33 months in the favorable group.
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Table 5. Multivariable analyses of IL-8, VEGF, and DFS.
SNP
Multivariable Analysis
n Adjusted RR Adjusted p Value Median DFS (Months)(95% CI)
IL-8 AA = unfavorable 14 2.817 (1.278–6.168) 0.010 33 (19.6–44.4)
IL-8 AT/TT = favorable 111 1 (reference) 20 (0.0–40.1)
VEGF TT/CT = unfavorable 46 1.351 (0.736–2.480) 0.332 20 (12.0–28.0)
VEGF CC = favorable 79 1 (reference) 39 (10.2–67.8)
SNP
Combined Analysis
n Adjusted RR Adjusted p Value Median DFS (Months)(95% CI)
0 unfavorable 70 1 (reference) 0.034 58 (32.4–83.6)
1 unfavorable 54 1.853 (1.045–3.284) 20 (13.8–26.2)
2 unfavorable 3 4.910 (1.047–23.031) 7 (0.0–10.0)
Adjusted: based on cirrhosis, T-status, and HCC tumor nodes, which were significant in DFS. Results of the regression
analyses are given as relative risk with 95% confidence interval. Bold is used to highlight significant results.
2.5. Analysis of Other Tested Germline Polymorphisms
In total, 10 genes were tested; however, none of the further genes showed any relevant association
with DFS or OS. The detailed data are presented in Table 4.
3. Discussion
In this study, we aimed to clarify the impact of angiogenesis- and hypoxia-associated germline
polymorphisms on tumor recurrence in HCC patients who underwent partial hepatectomy. Here,
we demonstrate that a proangiogenic and functional germline polymorphism of the IL-8 gene
significantly correlates with DFS in HCC patients undergoing curative-intent surgery.
Despite recent advancements in the surgical treatment of HCC, the high rate of tumor recurrence
results in an overall poor clinical prognosis [3]. Although great efforts have been made to optimize
patient selection based on clinical and molecular parameters, data on how germline polymorphisms
influence clinical outcomes after surgical resection for HCC are scarce [41]. The prominent role of
tumor angiogenesis in HCC biology is reflected in the prominent arterial neo-vascularization of
HCC as one of the hallmarks of malignant hepatocyte transformation [42]. Targeted agents such
as sorafenib, a small-molecule multityrosine kinase inhibitor, have been employed in the treatment
of advanced HCC [17,43,44], and more recently, the administration of atezolizumab, a checkpoint
inhibitor, in combination with an anti-VEGF antibody (bevacizumab) showed promising results [13].
VEGF is one of the main regulators of tumor angiogenesis and is regulated by a large variety of
transcription factors such as HIF-1, nuclear factor κB (NF-κB), and signal transducer and activator
of transcription 3 (STAT3) [14]. Activation of the VEGF signaling pathway leads to endothelial
cell proliferation, migration, and formation of new vessels [45,46]. While the level of circulating
VEGF protein is increased in HCC patients and has been linked to poor oncological outcomes [45],
the expression levels of VEGF protein also correlate directly with tumor size, metastasis, and poor
prognosis in various malignancies [47]. Functional DNA sequence variations within the VEGF gene
lead to altered serum levels and activity and, as such, also affect clinical outcomes in different types of
malignant disease [48,49]. The VEGF C + 936T SNP has been associated with an increased susceptibility
to breast, lung, and colon cancer as well as with a shorter disease-free survival in colon cancer [20,50].
In our study, VEGF C + 936T and the presence of the T/T or C/T alleles was associated with shorter
DFS in our univariable analysis but did not reach significance in the multivariable analysis. The DFS
was 20 months in individuals with T/T or C/T alleles, in contrast to C/C homozygote patients who had
a median DFS of 30 months.
IL-8, a member of the CXC chemokine family, is a potent and VEGF-independent mediator
of tumor angiogenesis. In tumor biology, IL-8 conveys direct effects on tumor cells, mediating the
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transition to a migratory, proliferative, or mesenchymal phenotype [51]. Furthermore, IL-8 modifies
the tumor microenvironment, encouraging the recruitment of pro-tumorigenic immune cells, such as
tumor-associated macrophages with an “M2-like” phenotype, ultimately leading to a positive feedback
loop with increased IL-8 production, as well as recruitment of cancer-associated neutrophils, which,
in turn, contribute to angiogenesis and invasion through the secretion of matrix metalloproteinase
(MMP)-9 [52,53]. Furthermore, IL-8 conveys direct proangiogenic, chemotactic effects on endothelial
cells via its receptors CXCR1 and -2 [51]. Most studies on IL-8 in HCC focus on the prognostic role of
IL-8 expression and on the inhibition or activation of IL-8 in HCC models and cell lines [22,23,38,54,55].
As such, the findings of different groups have linked increased serum levels of IL-8 with tumor
invasion, recurrence, and metastases [22,55]. Only scarce evidence is available on the prognostic
role of IL-8 germline SNPs in HCC patients undergoing curative-intent surgery [56–58]. In 2000,
Hull et al. identified the functional role of a common polymorphism IL-8 T-251A bp upstream of the
IL-8 transcriptional start site, with over 50% of the United Kingdom population being heterozygous.
Their experimental data suggested the association of the IL-8 T-251A A allele with increased IL-8
production [59]. Furthermore, high-expression variants of IL-8 T-251A (A/A) are linked to tumor
recurrence and poor clinical outcome in various gastrointestinal malignancies, including colon and
gastric cancer [18,20]. In patients with HCC, the homozygous IL-8-A/A allele was recently associated
with a favorable clinical effect on transcatheter arterial chemoembolization (TACE) efficacy and lower
levels of serum AFP [60]. Angiogenesis Liver CancEr 2 (ALICE-2), a retrospective multicenter study of
210 patients with advanced HCC, recently identified a panel of H1F-1α, VEGF-A, VEGF-C, VEGFR-1,
and VEGFR-3 variants to be associated with better response to sorafenib treatment [29]. The present
study demonstrated that patients with high-expression variants of IL-8 T-251A (A/A) developed
significantly earlier tumor recurrence after partial hepatectomy with curative intent. On average,
individuals with the homozygous minor allele A/A were recurrence-free for 20 months, compared to
32-month RFS in patients with at least one “protective” T allele (p-value: 0.034 in multivariable analysis).
The findings of this study should be interpreted in light of the potential limitations; nonetheless,
this type of pilot study is an ideal forum for testing a novel hypothesis and generating data that
need to be confirmed in a prospective study. First, our findings are based on a relatively small but
homogeneous number of Central European HCC patients; and secondly, we examined only 10 genes
within the angiogenesis pathway. While it is recognized that the observed associations and patterns
require confirmation with an independent dataset, we have taken care to select candidate genes with
a documented role in tumor angiogenesis that were also found to be associated with prognosis in
previous studies [61].
4. Materials and Methods
4.1. Patients
Between 2010 and 2017, unrelated patients with localized HCC and no signs of systemic disease
were treated with first-line surgical resection at the University Hospital of the Rheinisch-Westfälische
Technische Hochschule (RWTH) Aachen (UH-RWTH) and were retrospectively included in this study.
Clinico-pathological and follow-up data were obtained from a prospectively managed institutional
database and analyzed retrospectively [62]. Clinical staging was performed according to the criteria
of the International Union Against Cancer (UICC), BCLC, and Milan criteria. An experienced
pathologist (N.T.G.) reviewed the histological specimens of the cohort (n = 127) to confirm the diagnosis.
Patient samples were provided by the Institute of Pathology (UH-RWTH) and the institutional Biobank
(RWTH-cBMB). The study was conducted in accordance with the requirements of the Institutional
Review Board of the RWTH Aachen University (EK 360/15), the current version of the Declaration of
Helsinki, and the guidelines for good clinical practice.
Cancers 2020, 12, 3826 10 of 14
4.2. Selection of Candidate Polymorphisms
SNPs for molecular testing were selected based on our previous studies [20] and with a focus on
tumor angiogenesis based on VEGF-dependent and -independent IL-8 pathways and the hypoxia-driven
pathway. Besides well-documented function of the selected genes in the above-mentioned pathways,
proof of a biological relevance of the respective SNPs was a necessary prerequisite. Additionally,
the frequency of the polymorphism had to be high enough to allow a meaningful statistical analysis [20]
(Tables 1 and 6).
Table 6. Forward and reverse primer sequences and restriction enzymes used.
No. Gene Allele Primer Forward Primer Reverse Annealing Temp. Enzyme
1 IL-8 251 A > T TTG TTC TAA CAC CTG CCA CTC T GGC AAA CCT GAG TCA TCA CA 60 ◦C Mfe I
2 VEGF +936 C > T AGA CTC CGG CGG AAG CAT TGT ATG TGG GTG GGT GTG TC 60 ◦C Nla III
3 EGFR -497 G > A TGC TGT GAC CCA CTC TGT CT CCA GAA GGT TGC ACT TGT CC 60 ◦C Bstni
4 EGFA 61G A > G CAT TTG CAA ACA GAG GCT CA TGT GAC AGA GCA AGG CAA AG 60 ◦C Alu Ia
5 p53 C > G ATC TAC AGT CCC CCT TGC CG GCA ACT GAC CGT GCA AGT CA 60 ◦C Bstni
6 CXCR1 G > C CTC ATG AGG ACC CAG GTG AT GGT TGA GGC AGC TAT GGA GA 60 ◦C Alu I
7 IL-1b C > T GTT GTC ATC CAG ACT TTG ACC TTC AGT TCA TAT GGA CCA GA 60 ◦C Taq1
8 HIF1 A588T C > T CCC AAT GGA TGA TGA CTT CC AGT GGT GGC ATT AGC AGT AGG 60 ◦C Tsp-45 I
9 IL-10 T > G GAGCACTACCTGACTAGCATATAAG GTGGGCTAAATATCCTCAAAGT 60 ◦C RSAI
10 IL-6 G > C GCC TCA ATG ACG AC TCA TGG GAA AAT CC 60 ◦C NiaIII
Abbreviations used: VEGF, vascular endothelial growth factor; EGF, epidermal growth factor; EGFR, epidermal
growth factor receptor; IL-1/6/8/10, interleukin-1/6/8/10; CXC2, chemokine receptor; HIFa, hypoxia-inducing factor
alpha; p53, protooncogene 53.
4.3. Genotyping
From 127 formalin-fixed paraffin-embedded (FFPE) HCC samples, genomic DNA was extracted
using the QIAmp DNA Isolation Kit (Qiagen, CA, USA) according to the manufacturer’s protocol.
DNA quality was determined photometrically (NanoDrop, Thermo Fisher, MA, USA). Samples were
analyzed with the polymerase chain reaction–restriction fragment length polymorphism (PCR-RFLP)
technique. After PCR amplification of probes using forward and reverse primers, the products were
digested with restriction enzymes (New England Biolab, MA, USA). Reaction products were separated
on a DNA Stain G (SERVA, Heidelberg, Germany) stained 4% agarose gel at 120 mV for 60 min and
visualized under UV light using a GelDoc system (Bio-Rad Laboratories GmbH, Feldkirchen, Germany).
See Table 6 for forward and reverse primers, annealing temperatures, and restriction enzymes.
4.4. Study Endpoints and Statistical Analysis
The primary endpoint of this study was DFS, calculated from the date of surgery to the date of
the first recurrence. Patients who did not recur were censored at the time of death or at last follow-up.
The secondary endpoint was OS, defined as the period from surgery to the date of death from any
cause or the last contact if the patient was alive.
Categorical data are presented as numbers and percentages and were compared using the
chi-squared test, Fisher’s exact test, or linear-by-linear association according to scale and number
count. Data derived from continuous variables are presented as mean and standard deviation and
comparisons between different time points were made using the Mann–Whitney U test. The association
between each SNP and DFS and OS was examined using Kaplan–Meier curves and log-rank tests.
For polymorphisms with a genotype frequency (homozygous minor allele) of <10%, the associations
between genotypes and clinical outcome were analyzed in a dominant model. Otherwise, they were
analyzed in a codominant or additive model.
Survival curves were generated using the Kaplan–Meier method and compared with the log-rank
test. Univariable and multivariable associations of factors with patient survival and tumor recurrence
were assessed using Cox proportional hazard models. Hazard ratios are presented with 95% confidence
intervals (CI). Variables yielding significance in the univariable analysis were included in the
multivariable analysis. The level of significance was set to p < 0.05. Analyses were performed
using SPSS Statistics 23 (IBM Corp., Armonk, NY, USA).
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5. Conclusions
Notwithstanding the aforementioned limitations, we have identified polymorphisms in IL-8
to be associated with tumor recurrence in HCC patients undergoing curative-intent surgery. Thus,
the analysis of angiogenesis-related germline gene polymorphisms may facilitate more sophisticated
patient selection by identifying patients at high risk for HCC recurrence. One might speculate that
this subgroup of patients could potentially benefit from adjuvant anti-VEGF (e.g., bevacizumab)
therapeutics. Despite these encouraging findings from our pilot study, independent, larger, controlled
prospective biomarker-embedded clinical trials are warranted to validate our observations.
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